Annovis Bio, Inc. Income Statement
ANVS|6 years of annual SEC 10-K data (FY2020-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 6 fiscal years. All figures from audited SEC 10-K filings.
Annovis Bio, Inc. reported $0 in revenue and $29M in net loss for FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -9.28 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| SG&A Expense | $4.5M | $6.2M | $9.0M | $9.0M | $3.6M | $829.4K |
| R&D Expense | $25.2M | $38.8M | $16.5M | $16.5M | $3.1M | $776.3K |
| Operating Income | -$29.7M | -$45.0M | -$25.5M | -$25.5M | -$6.6M | -$1.6M |
| Income Tax | $0 | - | - | - | - | - |
| Net Income | -$28.9M | -$56.2M | -$25.3M | -$25.3M | -$5.5M | -$991.0K |
| EPS (Basic) | -$2.02 | -$6.23 | -$3.10 | -$1.90 | -$0.87 | - |
| EPS (Diluted) | -$2.31 | -$6.23 | -$3.10 | -$1.90 | -$0.87 | -$3.51 |
| Shares Outstanding | 14.1M | 10.5M | 8.2M | 8.1M | 6.9M | 282.6K |